Round: Series A
Investors Lead: EcoR1 Capital, UBS Oncology Impact Fund
Others: F2 Ventures, Redmile Group, Samsara BioCapital
What startup does: Creates, operates portfolio of cell and gene therapy companies by partnering with leading academic researches, medical centers and entrephenuer.
Fund plans: to acquire new companies in its portfolio